US Cardiologists Issue New Guidelines for How to Manage Cholesterol: What Changed in 2026?

 US Cardiologists Issue New Guidelines for How to Manage Cholesterol: What Changed in 2026?

Meta Description: New 2026 ACC/AHA cholesterol guidelines introduce updated LDL targets, earlier treatment, PREVENT-ASCVD risk assessment, Lp(a) testing and expanded cholesterol management strategies.

Focus Keyword: new cholesterol guidelines 2026

Secondary Keywords: 2026 cholesterol guidelines, ACC AHA cholesterol guidelines, LDL cholesterol targets, cholesterol management, statin guidelines, PREVENT-ASCVD, lipoprotein(a), ApoB

New US Cholesterol Guidelines Released

The American College of Cardiology (ACC), American Heart Association (AHA), and other leading medical organizations have issued new guidelines for managing dyslipidemia in 2026.

The updated 2026 ACC/AHA Guideline on the Management of Dyslipidemia replaces the previous 2018 blood cholesterol guideline and expands the focus beyond LDL cholesterol to include triglycerides, lipoprotein(a), apolipoprotein B and overall cardiovascular risk.

The new recommendations emphasize earlier prevention, personalized risk assessment and lower cholesterol targets for people at higher cardiovascular risk.

What Are the Biggest Changes?

1. Doctors Are Encouraged to Treat Cholesterol Earlier

The new guideline emphasizes reducing lifelong exposure to atherogenic lipoproteins.

Lifestyle counseling should begin early, while pharmacologic treatment may be considered in selected young adults with significantly elevated LDL cholesterol or a strong family history of premature cardiovascular disease.

This represents a shift from focusing primarily on short-term cardiovascular risk toward considering the cumulative effect of cholesterol exposure over a person's lifetime.

2. A New Risk Calculator Replaces the Older Pooled Cohort Equations

For adults aged 30 to 79 years without established ASCVD or subclinical atherosclerosis and with LDL-C between 70 and 189 mg/dL, the guideline recommends using the PREVENT-ASCVD equations for 10-year cardiovascular risk estimation.

The PREVENT-ASCVD model categorizes 10-year risk as:

Low: less than 3%

Borderline: 3% to less than 5%

Intermediate: 5% to less than 10%

High: 10% or higher

Doctors are encouraged to combine the calculated risk with individual risk factors and, when appropriate, coronary artery calcium testing before making treatment decisions.

3. LDL Cholesterol Targets Are Back

One of the major changes is the return of specific LDL-C and non-HDL-C treatment goals.

The percentage reduction in LDL cholesterol remains important, but patients are also assigned cholesterol targets according to their cardiovascular risk. Higher-risk patients generally have lower LDL-C goals.

For people with established cardiovascular disease who are at very high risk, the recommended LDL-C goal is below 55 mg/dL, with a non-HDL-C goal below 85 mg/dL.

For patients with clinical ASCVD who are not at very high risk, an LDL-C goal below 70 mg/dL is recommended.

4. More People May Be Considered for Statin Therapy

The updated risk thresholds could result in more adults being considered for cholesterol-lowering treatment.

For primary prevention, lipid-lowering therapy can be considered in adults with a 10-year PREVENT-ASCVD risk of 3% to less than 5%, following individualized discussion.

For those with a 10-year risk of 5% to less than 10%, lipid-lowering therapy should generally be considered after discussing the potential benefits and risks with a clinician.

A recent analysis reported that applying the new recommendations could substantially increase the number of US adults who qualify for statin treatment.

5. Lipoprotein(a) Testing Is Now More Important

The new guideline places greater emphasis on lipoprotein(a), or Lp(a), an inherited risk factor associated with cardiovascular disease.

The guideline recommends that adults have Lp(a) measured at least once in their lifetime to help identify additional cardiovascular risk.

An elevated Lp(a) level can provide important information when doctors are deciding how aggressively to manage other cardiovascular risk factors.

6. ApoB Testing Can Help Identify Hidden Risk

The guideline also recognizes a role for apolipoprotein B (ApoB) testing.

ApoB may be particularly useful in people with:

High triglycerides

Diabetes

Low achieved LDL-C

Residual cardiovascular risk despite apparently controlled cholesterol

ApoB can help identify atherogenic particle burden that may not be fully reflected by a standard lipid panel.

7. Coronary Calcium Scoring Has an Expanded Role

Coronary artery calcium (CAC) scoring can help doctors reclassify cardiovascular risk when the decision about cholesterol treatment is uncertain.

A CAC scan detects calcium deposits in the coronary arteries, which can provide evidence of underlying coronary atherosclerosis.

The new guideline expands the use of CAC scoring as part of individualized risk assessment.

8. Triglycerides Remain an Important Part of Cholesterol Management

The new recommendations address dyslipidemia more broadly rather than focusing only on LDL cholesterol.

For people with persistently elevated triglycerides, statin therapy remains the foundation of pharmacologic treatment for reducing ASCVD risk, alongside lifestyle modification.

Very high triglyceride levels also raise concerns about pancreatitis. Additional triglyceride-lowering treatment may be considered, particularly when triglycerides reach 1,000 mg/dL or higher.

What About People Who Already Have Heart Disease?

People with previous heart attacks, strokes or other forms of established ASCVD generally require more intensive cholesterol management.

High-intensity statin therapy remains an important part of secondary prevention.

If LDL cholesterol remains above the desired target despite maximally tolerated statin therapy, additional medications such as ezetimibe, PCSK9-targeting therapies or bempedoic acid may be considered depending on the patient's circumstances and the amount of additional LDL lowering needed.

Lifestyle Changes Still Matter

Despite the increased emphasis on medications and cholesterol targets, lifestyle remains a central part of the new recommendations.

Important measures include:

Eating a heart-healthy diet

Increasing physical activity

Maintaining a healthy body weight

Avoiding tobacco exposure

Managing blood pressure

Controlling diabetes

Limiting saturated and trans fats

Increasing intake of vegetables, fruits, whole grains and other nutrient-rich foods

Medication does not replace healthy lifestyle habits. Instead, lifestyle modification and lipid-lowering treatment are often used together.

What Should Patients Do Now?

People should not start, stop or change cholesterol medication based solely on an online article or a cholesterol number.

Instead, discuss your results with a healthcare professional. A complete assessment may include:

LDL-C and the complete lipid profile

Overall cardiovascular risk

Blood pressure and diabetes status

Family history of premature cardiovascular disease

Lp(a), when appropriate

ApoB, when useful

Coronary artery calcium scoring in selected patients

Lifestyle and other cardiovascular risk factors

The appropriate LDL-C target and treatment plan depend on the individual's overall cardiovascular risk.

Bottom Line

The 2026 ACC/AHA dyslipidemia guideline represents a major update in cholesterol management in the United States.

The new approach emphasizes earlier intervention, individualized cardiovascular risk assessment, specific LDL-C targets, Lp(a) testing, selective ApoB testing, coronary calcium scoring and broader management of triglycerides and other atherogenic lipoproteins.

For many patients, the key message is simple: don't look at cholesterol in isolation. Your overall cardiovascular risk determines how aggressively it should be managed.

Frequently Asked Questions

What is the new cholesterol guideline for 2026?

The 2026 ACC/AHA multisociety guideline replaces the 2018 cholesterol guideline and provides updated recommendations for LDL cholesterol, triglycerides, Lp(a), ApoB and cardiovascular risk assessment.

What LDL level is recommended under the new guidelines?

The target depends on cardiovascular risk. For very-high-risk patients with established ASCVD, the LDL-C goal is below 55 mg/dL. For many patients with clinical ASCVD who are not at very high risk, the goal is below 70 mg/dL.

At what age should cholesterol risk be assessed?

The new guideline emphasizes earlier assessment and uses the PREVENT-ASCVD equations for adults aged 30–79 years who meet the specified criteria.

Should everyone with high cholesterol take a statin?

No. Treatment decisions depend on LDL-C levels, overall cardiovascular risk, existing cardiovascular disease, risk-enhancing factors, lifestyle and patient-clinician discussion.

Is Lp(a) testing recommended?

The guideline recommends measuring Lp(a) at least once during a person's lifetime because elevated Lp(a) can identify additional cardiovascular risk.

Do the new guidelines replace lifestyle changes?

No. Lifestyle optimization remains a fundamental component of cardiovascular risk reduction, whether or not medication is prescribed.

Medical Disclaimer: This article is for general educational purposes and does not replace individualized medical advice. Cholesterol treatment should be determined in consultation with a qualified healthcare professional.